Multiple system atrophy (MSA): Year of the Zebra 2025

Chapters:

Watch video only

Introduction0:00–1:03

Multiple system atrophy or M SA. For short is a neurodegenerative disorder that affects a person's movement, sense of balance and regulation of body functions like BP, bowel and bladder control and breathing.
It's part of a group of movement disorders called Parkinson plus syndromes, which causes parkinsonism plus other clinical features.
The exact mechanism why it happens isn't completely understood, but it's believed to result from the abnormal buildup of a protein called alpha synuclein within glial cells, which are cells that support and protect the central nervous system.
This buildup mainly affects the areas of the brain responsible for voluntary movement, balance and coordination, as well as the autonomic nervous system, which is responsible for involuntary processes like BP, breathing and digestion.
Ultimately, this buildup leads to widespread brain damage. Now, symptoms of M SA typically begin around the age of 50 tend to progress rapidly over the course of 5 to 10 years.

Clinical Manifestations 1:03–2:30

Clinically, M SA can present in two different ways. Most individuals experience symptoms that resemble those of Parkinson disease, including resting tremor, rigidity, slowness of movement and postural instability, which often leads to a stooped posture and an increased frequency of falls.
Other people experience symptoms related to the loss of cerebellar function. This can manifest as poor hand eye coordination, difficulty with fine motor tasks like buttoning a shirt, involuntary eye movements known as nystagmus and a wide based gait.
Due to poor balance. Both subtypes of M SA share signs of autonomic system failure, which may include fainting or dizziness when standing due to low BP, known as orthostatic hypotension, impotence and urinary incontinence or retention in advanced stages.
Individuals may develop voice tone changes as well as difficulty speaking and swallowing due to weakness in the muscles in the mouth and throat.
In general, M SA tends to progress more rapidly than Parkinson disease and most people require walking aids such as a cane or walker within a few years of symptoms.
Beginning diagnosis of M SA can often be difficult. It relies on a combination of clinical findings and neuroimaging tests including a brain MRI or pet scan to rule out other neurodegenerative disorders with overlapping symptoms like Parkinson disease.

Diagnosis 2:30–2:48

Treatment of M SA focuses on improving quality of life as no medications have been proven to stop the progression of the disease.

Treatment 2:48–3:48

Levodopa. A treatment used in Parkinson disease is often used to improve motor function in the early stages but its efficacy generally decreases over time.
Orthostatic hypotension can be managed with compression, stockings and lifestyle changes such as increasing salt and fluid intake and avoiding standing up too quickly.
In severe cases, medications like fludrocortisone or mione may also be given to help increase BP. In advanced stages.
Individuals may have significant difficulties with swallowing and may need a feeding tube for nutritional support as well as continuous positive airway pressure or CPAP to prevent the airways from collapsing during sleep.
Likewise, they may require assistive walking devices such as walkers and wheelchairs. All right.
As a quick recap, MSA is a rapidly progressive neurodegenerative disorder which causes parkinsonism plus loss of autonomic function, resulting in orthostatic hypotension, impotence and urinary incontinence or retention diagnosis.

Review3:48–4:17

Relies on a combination of clinical findings and neuroimaging tests. Treatment aims to relieve symptoms as there is no definitive cure and may include medications and supportive care.